TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36669872
Drug: Migalastat treatment
Normalized name: migalastat
DrugBank: Migalastat (DB05018)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Migalastat treatment for 18 months
Study: 36670100
Drug: SARS-CoV-2 vaccination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 vaccination in patients treated with immunotherapy (IO)
Study: 36670495
Drug: PHYCOCARE® (phycocyanin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHYCOCARE® (phycocyanin) during oxaliplatin-based chemotherapy
Study: 36670495
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during oxaliplatin-based chemotherapy
Study: 36673992
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy (NRT) use during the initial intervention
Study: 36674120
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release with Findings-Oriented Orthopedic Manual Therapy (OMT) combined with Foam Roller (FR)
Study: 36678170
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day ISF Supplement
Study: 36678170
Drug: 50 mg/day
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/day ISF Diet
Study: 36678170
Drug: ISF Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISF Supplement among women enrolled within 5 years of menopause
Study: 36678191
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of EGCG daily alone
Study: 36678191
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of EGCG daily with clomiphene citrate 100 mg for 5 days
Study: 36678191
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of EGCG daily with Letrozole 5 mg for 5 days
Study: 36678638
Drug: Rifampicin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin at 35 mg/kg (HR35ZE group)
Study: 36678638
Drug: Rifampicin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin at 10 mg/kg (historical HR10ZE group)
Study: 36678659
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy applied once a week for four sessions with orabase cream
Study: 36678659
Drug: Low-power laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-power laser application with orabase cream
Study: 36679862
Drug: MVC-COV1901 vaccine
Normalized name: MVC-COV1901
DrugBank: MVC-COV1901 (DB15854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVC-COV1901 vaccine (two doses, 28 days apart)
Study: 36680581
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg + Palbociclib
Study: 36680581
Drug: Fulvestrant 500
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant 500 mg + Placebo
Study: 36680620
Drug: Ciprofol-0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol-0.3 mg/kg
Study: 36680620
Drug: Ciprofol-0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol-0.4 mg/kg
Study: 36680620
Drug: Ciprofol-0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofol-0.5 mg/kg
Study: 36680620
Drug: Propofol-2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-2.0 mg/kg
Study: 36680620
Drug: Propofol-2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-2.5 mg/kg
Study: 36680919
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg DHA
Study: 36681093
Drug: ABNCoV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABNCoV2 vaccine (6 μg, 12 μg, 25 μg, 50 μg, or 70 μg)
Study: 36681093
Drug: ABNCoV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABNCoV2 vaccine (25-70 μg)
Study: 36681093
Drug: ABNCoV2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABNCoV2 vaccine
Study: 36681173
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor
Study: 36681173
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy with ASA and ticagrelor
Study: 36681446
Drug: Low-dose BMMNC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BMMNC
Study: 36681446
Drug: High-dose BMMNC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BMMNC
Study: 36681445
Drug: leriglitazone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: leriglitazone (150 mg starting dose, adjusted to achieve plasma concentrations of 200 μg·h/mL)
Study: 36681529
Drug: TAK-003 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 and HAV vaccine on Day 1, TAK-003 on Day 90 (Group 3)
Study: 36681529
Drug: HAV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAV vaccine and placebo on Day 1, placebo on Day 90 (Group 1)
Study: 36681529
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (HAV vaccine)
Study: 36681529
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (TAK-003 and HAV vaccine)
Study: 36681529
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of HAV vaccine and TAK-003
Study: 36681798
Drug: Metformin extended
Normalized name: metFORMIN Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin extended release (1000 mg/day)
Study: 36682096
Drug: ODX 3
Normalized name: Oxycodone hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODX 3 mg/kg
Study: 36682096
Drug: ODX 6
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ODX 6 mg/kg
Study: 36682096
Drug: ODX 9
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ODX 9 mg/kg
Study: 36682262
Drug: Azithromycin (once-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (once-weekly oral, weight-based dosing for 48 weeks)
Study: 36682492
Drug: Digital storytelling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital storytelling intervention (12-min video and five monthly text messages)
Study: 36682596
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of β-blocker therapy
Study: 39645270
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of β-blocker therapy
Study: 36682675
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (MT) intervention, single session for 20-45 minutes
Study: 36682681
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) 600 mg twice on day 1, followed by 400 mg daily for 29 days.
Study: 36683090
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of escitalopram (n=32)
Study: 36683291
Drug: KW-6356 (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-6356 (specific dosage and duration not available)
Study: 36683419
Drug: AZD7442 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (300 mg intramuscularly)
Study: 36683419
Drug: Placebo (salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (salt solution)
Study: 36684710
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of power and strength-based exercises
Study: 36685528
Drug: Targeted-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted-release formulation (TRF) of budesonide
Study: 36685528
Drug: Systemic corticosteroid
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic corticosteroid treatment
Study: 36685541
Drug: Serplulimab plus
Normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab plus chemotherapy (etoposide and carboplatin)
Study: 36686711
Drug: Evolocumab, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab, dosage and duration not available
Study: 36686792
Drug: Carbon nanoparticle
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon nanoparticle suspension injection (CNSI)
Study: 36687215
Drug: E-learning intervention
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E-learning intervention consisting of three modules administered at baseline, 6 and 12 weeks.
Study: 36687403
Drug: COVID-19 Rehab
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 Rehab Formula (CRF) along with certain pre-defined Chinese medicine for 8 weeks
Study: 36687442
Drug: Gold weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold weight implant (GWI)
Study: 36687454
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme supplements (PES) - pancrelipase co-administered with omeprazole
Study: 36687807
Drug: Individual video-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual video-based case conceptualization with a web-based program based on Acceptance and Commitment Therapy (ACT), combined with treatment as usual.
Study: 36687807
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual only.
Study: 36687887
Drug: MCRR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCRR therapy for 20 minutes and pelvic floor exercises for 20 minutes, three times a week for 4 weeks.
Study: 36687887
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (same application as in Group A without emitting any waves) for 20 minutes, three times a week for 4 weeks.
Study: 36688371
Drug: MEDI6570 (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6570 (10, 30, 90, 250, or 500 mg single ascending doses; 90, 150, or 250 mg multiple ascending doses once monthly for 3 months)
Study: 36688371
Drug: MEDI6570 (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI6570 (after 3 doses)
Study: 36689214
Drug: Biosimilar natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Biosimilar natalizumab (biosim-NTZ), 300 mg, intravenous infusion every 4 weeks from week 0 to week 44.
Study: 36689214
Drug: Reference natalizumab
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Reference natalizumab (ref-NTZ), 300 mg, intravenous infusion every 4 weeks from week 0 to week 44.
Study: 36689692
Drug: Tarlatamab (AMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarlatamab (AMG 757), administered in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts
Study: 36689726
Drug: Acalabrutinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib and high-frequency low-dose (HFLD) subcutaneous rituximab 50 mg administered twice a week for 6 cycles of 28 days
Study: 36689746
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise therapy (patient-tailored exercise programs, 3 times a week for 12 weeks)
Study: 36689746
Drug: High-dose exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose exercise therapy
Study: 36689746
Drug: Low-dose exercise
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose exercise therapy (patient-tailored exercise programs, 3 times a week for 12 weeks)
Study: 36690072
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (Hb <10 g/dL to Hb ≥10 g/dL)
Study: 36690072
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (Hb <7 g/dL to Hb ≥7 g/dL)
Study: 36690181
Drug: Cold soda
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold soda water solution
Study: 36690181
Drug: Any-temperature glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any-temperature glucose solution containing a tea bag
Study: 36690181
Drug: Room-temperature water-based
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Room-temperature water-based glucose solution
Study: 36690404
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) infusion at a rate of 0.4 µg/kg/hour until surgical haemostasis
Study: 36690406
Drug: Letermovir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letermovir treatment
Study: 36690734
Drug: Dexamethasone-sparing regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone-sparing regimen with NEPA (netupitant/palonosetron fixed combination)
Study: 36690839
Drug: TMPRSS6-targeted therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TMPRSS6-targeted therapy (specific intervention details not provided)
Study: 36690940
Drug: Video-delivered mental
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video-delivered mental health course based on cognitive behavioral techniques, no specific dosage or duration mentioned.
Study: 36691000
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (in patients with previous ASBO)
Study: 36691039
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based cognitive behavioral therapy (VR-CBT)
Study: 36691039
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive behavioral therapy (CBT)
Study: 36691127
Drug: Chess-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chess-based cognitive remediation training (CB-CRT) as a therapy add-on for 6 weeks
Study: 36691127
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual for AUD in a clinic
Study: 36691127
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual for TUD outpatient treatment
Study: 36691137
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser therapy with 'Latent inhibition' as anxiety-management technique
Study: 36691165
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric derisomaltose administered approximately 3 months prior to TAVI
Study: 36691165
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered approximately 3 months prior to TAVI
Study: 36691167
Drug: Standard HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HR assessment (stethoscope, gel-electrode ECG, pulse oximetry)
Study: 36691184
Drug: Pre-chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-chemotherapy
Study: 36692019
Drug: Delayed fractional
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed fractional (DFx) dosing schedule (0-1-6 month)
Study: 36692019
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing schedule (0-1-2 month)
Study: 36692475
Drug: Polypharmacy (defined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (defined as the concurrent use of eight or more medications)
Study: 36692475
Drug: One or
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One or more major potential drug interactions (PDIs)
Study: 36692939
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VR-ET)
Study: 36693403
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (HFNO or standard oxygen)
Study: 36693589
Drug: ACT+MBRP (Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT+MBRP (Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention)
Study: 36694613
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) followed by steroids
Study: 36694613
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) followed by anakinra
Study: 36694613
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) followed by infliximab
Study: 36695286
Drug: Control (pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (pharmacological therapy only)
Study: 36695396
Drug: Intermediate-dose LMWH
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose LMWH
Study: 36695396
Drug: Low-dose LMWH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose LMWH
Study: 36695625
Drug: ATG monotherapy
Normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG monotherapy (6 or 3 mg/kg body weight) without concomitant immunosuppression
Study: 36695682
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (100,000 IU every 2 weeks for 2 months, then monthly for 22 months)
Study: 36695682
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol (12,000 IU every 2 weeks for 2 months, then monthly for 22 months)
Study: 36696827
Drug: Shorter antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter antimicrobial treatment (≤10 days)
Study: 36696827
Drug: Longer antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longer antimicrobial treatment (>10 days)
Study: 36696827
Drug: Overall median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall median duration of antibiotic therapy
Study: 36696843
Drug: Self-report of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report of drug use
Study: 36696843
Drug: Self-report of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report of drug use among those with positive opioid UDS
Study: 36697048
Drug: Behavioural economics-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural economics-based incentives and text messages to support medication adherence
Study: 36697134
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor 2 (SST2) PET/MR imaging
Study: 36697207
Drug: JNJ-56136379 75
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 75 mg + nucleos(t)ide analogue (NA)
Study: 36697207
Drug: JNJ-56136379 250
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-56136379 250 mg + nucleos(t)ide analogue (NA)
Study: 36697215
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation (MR) consisting of a diagnostic multidisciplinary consultation and eight sessions of physical and occupational therapy.
Study: 36697694
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of maternal periodontal disease during pregnancy
Study: 36697694
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment after pregnancy)
Study: 36698135
Drug: High neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High neutralizing antibody (NAb) titers at days 37, 97, and 187 after symptom onset
Study: 36698168
Drug: Home-based tablet-based
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home-based tablet-based BCI intervention
Study: 36698168
Drug: Clinic-based tablet-based
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based tablet-based BCI intervention
Study: 36698194
Drug: Tobacco cessation
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobacco cessation pharmacotherapy (varenicline) paired with behavioral support
Study: 36698210
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation group therapy
Study: 36698447
Drug: Cleansing gel
Normalized name: salicylic acid 0.7 % Cleansing Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing gel containing salicylic acid 2%, zinc gluconate 0.2% and lipohydroxy acid 0.05%
Study: 36700571
Drug: Home-based pulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based pulmonary rehabilitation program with telecoaching (weekly phone calls from a physiotherapist)
Study: 36700734
Drug: BI 425809
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 25 mg once daily
Study: 36700734
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and digoxin alone
Study: 36701184
Drug: Over-the-counter pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Over-the-counter pain and indigestion medications